UCB Biopharma's Staccato Alprazolam Trial Targets Prolonged Seizures in Patients 12 and Older
A study is underway to evaluate the efficacy and safety of Staccato alprazolam in terminating seizure episodes in patients aged 12 and older.
Asset / Drug
Drug and asset intelligence for UCB with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.